Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flinn

Showing results (851-860 of 1,038) with videos related to

Pageof 104
Sort By:
Oncotarget|June 21, 2019
Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLLJohn C Byrd, Stephen Smith, Nina Wagner-Johnston, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2015
Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemiaJames S Blachly, Amy S Ruppert, Weiqiang Zhao, et al.
Pediatrics|September 30, 2024
Opioid Prescribing for Acute Pain Management in Children and Adolescents in Outpatient Settings: Clinical Practice GuidelineScott E Hadland, Rita Agarwal, Sudha R Raman, et al.
Blood|April 10, 2025
ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S Davids, Saad S Kenderian, Ian W Flinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicityJ C Byrd, T Murphy, R S Howard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2009
Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphomaY L Kasamon, R J Jones, R A Brodsky, et al.
Blood|December 2, 2017
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignanciesIan W Flinn, Susan O'Brien, Brad Kahl, et al.
Plos Genetics|July 24, 2025
Novel insights into post-myocardial infarction cardiac remodeling through algorithmic detection of cell-type composition shiftsBrian Gural, Logan Kirkland, Abigail Hockett, et al.
Seminars in Oncology|February 1, 2017
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Leukemia|June 16, 2012
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upR A Larson, A Hochhaus, T P Hughes, et al.
Pageof 104

Showing results (851-860 of 1,038) with videos related to

Sort By:
Pageof 104
Oncotarget|June 21, 2019
Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLLJohn C Byrd, Stephen Smith, Nina Wagner-Johnston, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2015
Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemiaJames S Blachly, Amy S Ruppert, Weiqiang Zhao, et al.
Pediatrics|September 30, 2024
Opioid Prescribing for Acute Pain Management in Children and Adolescents in Outpatient Settings: Clinical Practice GuidelineScott E Hadland, Rita Agarwal, Sudha R Raman, et al.
Blood|April 10, 2025
ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S Davids, Saad S Kenderian, Ian W Flinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicityJ C Byrd, T Murphy, R S Howard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2009
Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphomaY L Kasamon, R J Jones, R A Brodsky, et al.
Blood|December 2, 2017
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignanciesIan W Flinn, Susan O'Brien, Brad Kahl, et al.
Plos Genetics|July 24, 2025
Novel insights into post-myocardial infarction cardiac remodeling through algorithmic detection of cell-type composition shiftsBrian Gural, Logan Kirkland, Abigail Hockett, et al.
Seminars in Oncology|February 1, 2017
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Leukemia|June 16, 2012
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upR A Larson, A Hochhaus, T P Hughes, et al.
Pageof 104